LAMPIASI, NADIA
 Distribuzione geografica
Continente #
AS - Asia 1.970
NA - Nord America 937
EU - Europa 461
SA - Sud America 362
AF - Africa 30
OC - Oceania 2
Totale 3.762
Nazione #
US - Stati Uniti d'America 894
SG - Singapore 766
CN - Cina 525
BR - Brasile 295
HK - Hong Kong 242
VN - Vietnam 178
IT - Italia 145
FR - Francia 110
NL - Olanda 93
KR - Corea 78
JP - Giappone 46
IN - India 43
AR - Argentina 33
GB - Regno Unito 26
DE - Germania 23
FI - Finlandia 19
CA - Canada 18
MX - Messico 14
EC - Ecuador 11
IL - Israele 11
BD - Bangladesh 10
KE - Kenya 9
ID - Indonesia 8
IQ - Iraq 8
UA - Ucraina 8
AE - Emirati Arabi Uniti 7
TR - Turchia 7
CO - Colombia 6
EG - Egitto 6
SA - Arabia Saudita 6
SE - Svezia 5
UZ - Uzbekistan 5
VE - Venezuela 5
ZA - Sudafrica 5
JO - Giordania 4
MA - Marocco 4
PH - Filippine 4
RU - Federazione Russa 4
AZ - Azerbaigian 3
BO - Bolivia 3
DK - Danimarca 3
JM - Giamaica 3
LT - Lituania 3
NP - Nepal 3
PE - Perù 3
PL - Polonia 3
TT - Trinidad e Tobago 3
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ES - Italia 2
HU - Ungheria 2
KZ - Kazakistan 2
LB - Libano 2
MY - Malesia 2
PK - Pakistan 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
TN - Tunisia 2
UY - Uruguay 2
BY - Bielorussia 1
BZ - Belize 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
GY - Guiana 1
IE - Irlanda 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
NO - Norvegia 1
NR - Nauru 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
YE - Yemen 1
Totale 3.762
Città #
Singapore 463
Santa Clara 402
Hong Kong 236
Hefei 199
Beijing 108
San Jose 105
Lauterbourg 80
Seoul 77
Ashburn 75
Ho Chi Minh City 69
Los Angeles 40
Hanoi 35
Tokyo 34
Dallas 30
São Paulo 25
Palermo 23
New York 20
Mumbai 15
Frankfurt am Main 11
Helsinki 11
Montreal 11
Minamishinagawa 10
Rio de Janeiro 10
Bengaluru 9
Nairobi 9
Buffalo 8
Cagliari 8
Haiphong 8
Lappeenranta 8
Orem 8
Quito 8
Atlanta 7
Belo Horizonte 6
Brasília 6
Da Nang 6
Porto Alegre 6
Amsterdam 5
Chennai 5
Contagem 5
Council Bluffs 5
Curitiba 5
Milan 5
Phoenix 5
Salvador 5
Tashkent 5
Belém 4
Charlotte 4
Denver 4
Goiânia 4
Mexico City 4
Poplar 4
Rome 4
Stockholm 4
Thái Bình 4
Thái Nguyên 4
Abu Dhabi 3
Amman 3
Anápolis 3
Baku 3
Bexley 3
Biên Hòa 3
Brooklyn 3
Buenos Aires 3
Bình An 3
Cairo 3
Chicago 3
Dhaka 3
Forest City 3
Guarulhos 3
Houston 3
Istanbul 3
Jacksonville 3
Johannesburg 3
Kyiv 3
La Paz 3
Manaus 3
Naples 3
Ninh Bình 3
Recife 3
Riyadh 3
Rosario 3
San Antonio 3
Santo André 3
Seattle 3
The Dalles 3
Acalanes Ridge 2
Ankara 2
Aparecida de Goiânia 2
Baltimore 2
Betim 2
Birmingham 2
Boardman 2
Bogotá 2
Braunschweig 2
Budapest 2
Bắc Giang 2
Bắc Ninh 2
Cabanatuan City 2
Camaçari 2
Campinas 2
Totale 2.391
Nome #
A new ginger extract characterization: immunomodulatory, antioxidant effects and differential gene expression 113
Inflammation and the Potential Implication of Macrophage-Microglia Polarization in Human ASD: An Overview 88
The sea urchin embryo and the cell stress responses: new perspectives 87
Macrophage Polarization: Learning to Manage It 2.0 86
Mirnas expression profiling in raw264.7 macrophages after nfatc1-knockdown elucidates potential pathways involved in osteoclasts differentiation 86
Macrophage polarization: learning to manage it 80
Sperimento...ergo sum: Studenti al banco di laboratorio 79
Cationic Solid-lipid nanoparticles as DNA carriers. 79
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells 76
Mast cell production of TNF-alpha induced by substance P evidence for a modulatory role of substance P-antagonists. 73
COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells. 61
New Strategies for Macrophage Re-Education in Cancer: An Update 61
Sensing melanoma cells with hyaluronic acid decorated magnetoplasmonic nanoassemblies: from diagnosis to future therapeutic applications 59
The novel NF-kB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. 58
The Alternative Faces of Macrophage Generate Osteoclasts 57
Neurotoxicity in marine invertebrates: An update 56
Gene Expression Profiling of NFATc1-Knockdown in RAW 264.7 Cells: An Alternative Pathway for Macrophage Differentiation 55
Long-Lasting Activity of ERK Kinase Depends on NFATc1 Induction and Is Involved in Cell Migration-Fusion in Murine Macrophages RAW264.7 55
Fluorescent Magneto-Plasmonic Cyclodextrin Nanohybrids for Liquid Biopsy-Based Early Detection of Melanoma 55
The Migration and the Fate of Dental Pulp Stem Cells 54
In silico insights and molecular characterization between IKK kinase and some ligands 54
Probing safety of nano-objects by defining immune responses of environmental organisms 52
Macrophage Polarization: Learning to Manage It 3.0 51
Osteoclasts differentiation from murine RAW 264.7 cells stimulated by RANKL: Timing and behavior 50
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway 47
Development of nimesulide loaded solid lipid nanoparticles. 46
MITF: an evolutionarily conserved transcription factor in the sea urchin Paracentrotus lividus 45
Interactions between Macrophages and Mast Cells in the Female Reproductive System 45
Substance P induces HO-1 expression in RAW 264.7 cells promoting switch towards M2-like macrophages 43
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. 42
Gli organismi viventi come esempio di plasticità e interazione con l'ambiente esterno 42
Mesenchymal Stem Cells: What We Have Learned and How to Manage Them 40
Toxic mineral elements in Mytilus galloprovincialis from Sicilian coasts (Southern Italy) 40
Regulation of the Phenotype and Function of Human Macrophages and Dendritic Cells by Exogenous Immunomodulators 40
The response to simulated hypogravity is dependent on the proliferation state and temperature in FRTL-5 thyroid cells 39
Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. 38
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. 38
Antitumor effects of DHMEQ, a novel NF-kB inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. 36
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. 36
Natural Molecules as IKK a/b Inhibitors useful in the Treatment of Inflammation 35
A factor secreted by human embryo stimulates cytokine release by uterine mast cell. 35
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 34
The molecular events behind ferulic acid mediated modulation of IL-6 expression in LPS-activated RAW 264.7 34
Cationic solid-lipid nanoparticles for gene delivery. 34
2015-2017 Accordo di cooperazione scientifica CNR/RFBR (Russian Foundation for Basic Research) : "Cell-cell fusion in vertebrate and invertebrate short-term cultures: ultrastructural, cellular and molecular analyses and role of ECM molecules, growth factors and miRNAs" 33
Molecular mechanisms of sorafenib action in liver cancer cells. 33
Inhibitory effect of neuraminidase on SP-induced histamine release and TNF-alpha mRNA in rat mast cells: evidence of a receptor-independent mechanism. 32
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells. 32
Cyclooxygenases in cancer 32
Microgravity and cellular homeostasis: effects of simulated hypogravity on FRTL-5 thyroid cells. 32
Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery 31
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells. 31
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells 31
Induction of apoptosis and inhibition of cells growth in human hepatocellular carcinoma cells by COX-2 inhibitors. 30
Interaction between Embryo Histamine Releasing Factor (EHRF) and uterine mast cell. 29
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 29
Dispersal of rat uterine mast cells and their functional response to an embryo-derived histamine releasing factor: a possible model for embryo implantation. 29
Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 29
Combination of DHMEQ and Celecoxib synergistically exert anti-tumoral effects in human hepatoma cells. 29
Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells 28
The selective COX-1 inhibitor SC-560 inhibits cell growth and induces apoptosis in human hepatocellular carcinoma cells. 28
Gene expression profiling of human liver cancer cells following celecoxib treatment. 28
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 28
Antitumor effects of the selective cyclooxygenase-1 inhibitor SC-560 is potentiated by inhibiton of MEK/ERK pathway in human hepatocellular carcinoma cells. 28
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells. 27
G. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. 27
Induction of Apoptosis and Inhibition of Cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors 27
The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells through redox-dependent signaling. 27
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 27
Solid-lipid nanoparticles for gene delivery to cells. 27
Poly (ADP-ribose) polymerase inhibition synergizes with the NF-kB inhibitor DHMEQ to kill hepatocellular carcinoma cells 26
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 26
The multikinase inhibitor Sorafenib exhibits a strong cytotoxic effect in liver cancer cells through a MEK/ERK signaling-independent mechanism 26
Effect of substance P on uterine mast cell cytokine release during the reproductive cycle. 26
Modulation of rat peritoneal mast cell and human basophil histamine release by estrogens. 25
DHMEQ and Celecoxib synergistically exert anti-tumoral activities in human liver cancer cells. 25
Inhibition of MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells. 25
Altered gene expression profiles in liver cancer cells upon sorafenib treatment. 25
Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells 24
INVOLVEMENT OF p38 AND JNK mapks PATHWAYS IN SUBSTANCE P-INDUCED PRODUCTION OF TNF - BY PERITONEAL MAST CELLS 24
Corrigendum to "Poly (ADP-ribose) polymerase inhibition synergizes with the NF-?B inhibitor DHMEQ to kill hepatocellular carcinoma cells" [Biochim. Biophys. Acta 1843 (2014) 2662-2673] 24
Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells 23
Growth suppression and apoptosis induction in human hepatoma cells by DHMEQ, a novel NF-KB inhibitor, is mediated through a ROS-dependent mechanism. 23
Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells 23
Microgravity and cellular homeostasis:effects of stimulated hypogravity on FRTL-5 thyroid cells. 23
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells 22
Substance P induces TNF-alpha and IL-6 production through NFkB in peritoneal mast cells 22
The selective COX-1 inhibitor SC-560 suppresses cell growth and induces apoptosis in human hepatocellular carcinoma cells. 21
Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies. 21
Solid lipid nanoparticles (SLNs) containing nimesulide: preparation, characterization and in cytotoxicity studies 20
United we stand: Adhesion and molecular mechanisms driving cell fusion across speciestand 20
HIF-1α as a Central Regulator of Monocyte Responses to Hypoxia 20
Histamine and tumor necrosis factor-alpha production from purified rat brain mast cells mediated by substance P. 20
Estrogens and EHRF are important factors for the Embryo Implantation Step. 20
The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells 20
DHMEQ, a novel NF-kb inhibitor, anticancer activity through induction of reactive oxygen species-dependent mechanism in human hepatoma cells. 20
Antigens of Euparipha pisana (snail). I. Identification of allergens by means of in vivo and in vitro analysis. 19
Oestradiol enhances in vitro the histamine release induced by embryonic histamine-releasing factor (EHRF) from uterine mast cells. 17
Poly (ADP-ribose) polymerase inhibition synergizes with the NF-kB inhibitor DHMEQ to kill hepatocellular carcinoma cells. 17
Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism 16
Totale 3.841
Categoria #
all - tutte 11.534
article - articoli 6.966
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 266
Totale 18.766


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202455 0 0 0 0 0 0 0 0 34 12 4 5
2024/20251.478 17 7 93 42 370 72 20 91 58 86 348 274
2025/20262.338 164 247 250 385 402 94 309 162 145 118 62 0
Totale 3.871